公开(公告)号：US20220378755A1

公开(公告)日：2022-12-01

申请号：US17761788

申请日：2020-09-18

Applicant: FORMA Therapeutics, Inc.

Inventor： George P. Luke ,  Suresh Babu

IPC: A61K31/436 ,  A61K9/00 ,  A61K9/20

Abstract: The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.

公开(公告)号：US20240131011A1

公开(公告)日：2024-04-25

申请号：US18125932

申请日：2023-03-24

Applicant: FORMA Therapeutics, Inc.

Inventor： George P. Luke ,  Suresh Babu

IPC: A61K31/436 ,  A61K9/00 ,  A61K9/20

CPC classification number: A61K31/436 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054

Abstract: The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.

公开(公告)号：US11795168B2

公开(公告)日：2023-10-24

申请号：US17482717

申请日：2021-09-23

Applicant: FORMA Therapeutics, Inc.

Inventor： George Luke ,  Suresh Babu

IPC: C07D471/04 ,  A61K9/48 ,  A61K9/16

CPC classification number: C07D471/04 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

Abstract: The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I). The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.